SICHUAN EXPRESS (00107): Zhang Lihu has been nominated for appointment as a candidate for non-executive director.
Sichuan Chengyu Expressway (00107) announced that Mr. Zhang Lihu was nominated for appointment as a candidate for a non-executive director of the company's ninth board of directors.
SICHUAN EXPRESS (00107) issued an announcement that Mr. Zhang Lihu has been nominated for appointment as a candidate for non-executive director of the company's ninth board of directors.
Related Articles
IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.
Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.
TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).
IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.
Suzhou Novosense Microelectronics (02676) announced its interim results, with a net profit attributable to the parent company of approximately 67.5918 million yuan, marking a turnaround from a loss to profit compared to the same period last year.
TYK MEDICINES-B(02410): The National Medical Products Administration has conditionally approved the marketing application for Dihydroartemisinin Mesylate Tablets (TY-9591 Tablets).
RECOMMEND
